Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo

Clinical Infectious Diseases

Volumn 33, Issue 12, 2001, Pages 2075-2077

  Zachary, K C ^a   Hanna, G J ^a   D'Aquila, R T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; CARBAMATES; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MUTATION; SULFONAMIDES; VIRAL LOAD;

EID: 0035893128     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/324510     Document Type: Article

References (9)

1. The N88S mutation in HIV-1 protease is associated with increased susceptibility to amprenavir
2. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
3. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
4. Genotype and phenotype of HIV-1 in ART experienced adults prior and following therapy with Ziagen added to stable background therapy
5. Analysis of possible predictors of response to abacavir in antiretroviral-experienced adults: Comparison of viral genotype, viral phenotype and patient treatment history
6. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG 302)
7. CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy
8. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
9. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632